Search

Author/Creator Ebata, K.

2. The development of a potent, KDR/VEGFR2-sparing RET kinase inhibitor for treating patients with RET-dependent cancers. (December 2016)

Authors:
Brandhuber, B.; Haas, J.; Tuch, B.; Ebata, K.; Bouhana, K.; McFaddin, E.; Williams, L.; Winski, S.; Brown, E.; Burkhard, M.; Nanda, N.; Hamor, R.; Sullivan, F.; Hanson, L.; Morales, T.; Vigers, G.; Wallace, R.D.; Blake, J.; Andrews, S.; Rothenberg, S.M.
Journal:
European journal of cancer
Issue:
Volume 69(2016)supplement 1
Page Start:
S144
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. The development of LOXO-195, a second generation TRK kinase inhibitor that overcomes acquired resistance to 1st generation inhibitors observed in patients with TRK-fusion cancers. (December 2016)

Authors:
Blake, J.; Kolakowski, G.R.; Tuch, B.; Ebata, K.; Brandhuber, B.; Winski, S.; Bouhana, K.; Nanda, N.; Wu, W.I.; Parker, A.; Hamor, R.; Larsen, P.D.; Sullivan, F.; DeWolf, W.; Neitzel, N.; Wollenberg, L.; Andrews, S.; Rothenberg, S.M.
Journal:
European journal of cancer
Issue:
Volume 69(2016)supplement 1
Page Start:
S144
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗